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Introduction
　Congenital factor VII deficiency is a hemorrhagic disease 
that was first reported by Alexander et al. in 1951. It is char-
acterized by a prolonged prothrombin time (PT; 1-step meth-
od) and a normal partial thromboplastin time. It presents 
with an autosomal recessive inheritance pattern, and bleed-
ing tendencies of varying severity are also seen. In addition, 
some reports have suggested that it can have serious adverse 
outcomes. The incidence of the condition is 1 in 500,000 
people, and about 280 cases from around the world, includ-
ing 40 involving patients from Japan, had been registered in 
the FVII Mutation Database (The Haemostasis Research 
Group, Medical Research Council Clinical Sciences Centre, 
London UK) as of 2004. 
　We report the case of a patient with congenital factor VII 
deficiency, which was diagnosed during preoperative blood 
tests for orthognathic surgery. The patient safely underwent 
MS#AMN 07163
Case Report
A case of sagittal splitting ramus osteotomy and genioplasty in a patient with 
congenital factor VII deficiency
Satoshi Rokutanda1. 3) , Masashi Yoshida1), Kazuto Kuroe2), Souichi Yanamoto3), Shin-ichi Yamada3), Toshihiro Kawano1. 3), 
Tomofumi Naruse3), Kosuke Obama4), Masahiro Umeda3)
1 Department of Oral and Maxillofacial Surgery, Imakiire General Hospital (Chief: Dr. Masashi Yoshida) 
2 Kuroe Orthodontic Clinic (Chief: Dr. Kazuto Kuroe)
3 Department of Clinical Oral Oncology, Unit of Translational Medicine, Nagasaki University Graduate School of Biomedical Sciences (Chief: Prof.
  Masahiro Umeda)
4 Department of Hematology, Imakiire General Hospital (Chief: Dr. Kosuke Obama)
　Blood coagulation factor VII is involved in the extrinsic clotting system, and congenital defects or deficiencies affecting blood 
coagulation factor VII are rare. We report the case of a patient who was diagnosed with factor VII deficiency based on a preop-
erative examination and then underwent factor VII replacement therapy and orthognathic surgery, together with a brief discus-
sion of the literature. 
　The patient was a 25-year-old woman. She presented to our hospital after being diagnosed with jaw deformity and underwent 
sagittal splitting ramus osteotomy and genioplasty under general anesthesia. Preoperative tests revealed an abnormally short 
prothrombin time. Blood tests detected very low coagulation factor VII activity (33%), and so the patient was diagnosed with fac-
tor VII deficiency. 
　We conducted preoperative factor VII replacement therapy to inhibit bleeding, and then the abovementioned surgical proce-
dure was performed safely. The operative time was 1 hour 30 minutes, and little intraoperative blood loss occurred. The patient’s 
postoperative course was good, e.g., no abnormal bleeding occurred, and she was discharged on postoperative day 7. 
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the orthognathic surgery after the administration of factor 
VII replacement therapy.
Case
　A 25-year-old woman visited an orthodontic doctor for 
corrective mandibular treatment. She exhibited mandibular 
protrusion, edge-to-edge occlusion, deviation of the mandi-
ble to the right, and an anterior crossbite. Cephalometric ra-
diographs showed mandibular prognathism due to lateral 
hypogrowth of the maxilla and anteroinferior hypergrowth 
of the mandible. After preoperative orthodontic treatment, a 
sagittal splitting ramus osteotomy and genioplasty under 
general anesthesia were planned. Preoperative hematologi-
cal tests detected a PT of 40% (in-hospital reference value: 
80–120%), an activated partial thromboplastin time (APTT) 
of 33.2 sec (in-hospital reference value: 28.0–45.0 sec), and 
a PT-international normalized ratio (PT-INR) of 1.58. The 
patient was therefore referred to our hematology department 
for further evaluation. 
　Abnormalities in extrinsic clotting factors were suspected, 
and additional blood tests revealed factor VII deficiency and 
decreased factor VII activity  (33%, in-hospital reference 
value: 75–140%) (Table 1). The patient had not suffered any 
prior episodes of spontaneous bleeding. To avoid bleeding 
during surgery, the patient was preoperatively supplemented 
with recombinant activated factor VII eptacog alpha (Novo-
Seven HI®; Novo Nordisk Pharma, Denmark). Additional 
factor VII and blood transfusions were prepared in case mas-
sive bleeding occurred.  Autologous blood preservation was 
not performed because the stored blood also exhibited factor 
VII deficiency.  
　On the day of surgery, the factor VII eptacog alpha prepa-
ration was administered at a dose of 30 μg/kg without ad-
verse effects. As a result, the patientʼs PT reached ≥200% 
and her PT-INR had improved to 0.80 after 20 minutes, con-
firming that her bleeding tendency had been suppressed. 
Sagittal splitting ramus osteotomy and genioplasty were per-
formed without causing abnormal bleeding. The operative 
time was 1 hour 30 minutes, and little intraoperative blood 
loss occurred. 
　A computed tomography scan performed on postoperative 
day 1 did not detect any signs of bleeding. During the first 2 
days after the operation, the right and left continuous suction 
drains removed 131 ml and 100 ml of blood, respectively. 
No additional factor VII preparations were administered, 
and the continuous suction drains were removed. Blood tests 
performed on postoperative day 7 showed a PT of 39% and 
Table 1. Blood test results
Table 2. Test result trends after the administration of factor VII
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a PT-INR of 1.60. The patient was discharged on postopera-
tive day 7. On postoperative day 14, the patient displyed fac-
tor VII activity of 16%, a PT of 34%, and a PT-INR of 1.79. 
In the second month after surgery, she demonstrated factor 
VII activity of 26%, a PT of 42%, and a PT-INR of 1.57. The 
patientʼs subsequent course was uneventful (Table 2). 
Discussion
　Congenital factor VII deficiency is a form of bleeding 
diathesis caused by a quantitative deficiency or qualitative 
(functional) abnormality in factor VII resulting from a muta-
tion in the blood coagulation factor VII gene. Factor VII is a 
vitamin K-dependent coagulation factor that is produced in 
the liver. Activated factor VII is central to the extrinsic co-
agulation activation mechanism and forms compounds with 
tissue factors and calcium ions on phospholipids and acti-
vates factor IX and factor X. Therefore, a characteristic of 
factor VII deficiency is that even though abnormalities are 
seen in the extrinsic coagulation system, the intrinsic coagu-
lation system functions normally. Furthermore, patients with 
factor VII deficiency exhibit reduced factor VII activity in 
their blood and a prolonged PT, but their APTT, clotting 
time, and fibrinogen levels are normal. 
　The bleeding symptoms of factor VII deficiency vary 
widely, with the most typical being nosebleeds, gingival 
bleeding, and subcutaneous bleeding. In severe cases, com-
plications such as intraarticular hemorrhaging, central ner-
vous system hemorrhaging, and hypermenorrhea can occur. 
Intracranial bleeding is frequently reported in children, and 
neonatal intracranial hemorrhaging on delivery can have se-
rious outcomes. In cases of frequent bleeding, maintaining a 
target factor VII level of around 20% is recommended, and 
Bauer found that hemostatic function is sufficiently main-
tained at 15–25%1). However, the severity of bleeding does 
not necessarily correspond with factor VII activity in the 
blood2). Thus, predicting the amount of bleeding is difficult. 
Fresh frozen plasma and prothrombin complex concentrate 
transfusions are used for replacement therapy, but some re-
ports have suggested that they do not result in any improve-
ment. The present report is the first to describe sagittal split-
ting ramus osteotomy and genioplasty in a patient with factor 
VII deficiency. Factor VII preparations have been demon-
strated to improve the bleeding tendencies of patients with 
congenital factor VII deficiency in cases of massive blood 
loss during childbirth or other occasions3). In addition, in pa-
tients with severe factor VII deficiency factor VII prepara-
tions are widely used to prevent bleeding in cases of hemor-
rhaging, surgery, trauma, or invasive treatment4). In general, 
the administration of 15–30 μg/kg of a factor VII prepara-
tion every 4–6 hours is recommended. In one reported case, 
a perioperative factor VII administration schedule was pro-
duced based on measurements of the rise in factor VII activ-
ity and its half-life before surgery5). Another study reported 
that there is no need to administer factor VII preparations in 
cases of minor surgery, even for patients with severe con-
genital factor VII deficiency2). Currently, no established 
guidelines explaining the indications, dosage, administration 
frequency, or administration intervals for factor VII prepara-
tions exist3). 
　In the present case, PT-INR was used as an indicator of 
bleeding tendency. Preoperatively, the patient exhibited fac-
tor VII activity of 33% and a PT-INR of 1.58. Due to the 
possibility of marked blood loss occurring during the planned 
operation, a factor VII preparation was administered preop-
eratively to attempt to normalize the patientʼs PT-INR. To 
prevent intra- and postoperative coagulation disorders, ad-
ditional recombinant activated factor VII preparations and 
blood transfusions were prepared. As a result, no abnormal 
bleeding occurred, and the additional administration of fac-
tor VII eptacog alpha was unnecessary. 
　Many reports have suggested that factor VII administra-
tion should be investigated in cases involving postoperative 
hemostasis. Patients with coagulation disorders who under-
go major surgery are at increased risk of clot formation, dis-
seminated intravascular coagulation, or exacerbation. 
　The procedure performed in the present case was consid-
ered to represent major surgery, and thus, a factor VII prepa-
ration was administered preoperatively.
　The half-life of recombinant activated factor VII is 3–4 
hours, which is shorter than those of all other coagulation 
factors. Thus, the frequent administration of factor VII is 
necessary to prevent bleeding. However, thrombosis and 
other side effects have been reported after the frequent ad-
ministration of factor VII6). In the present case, the use of 
elastic stockings and early ambulation were performed after 
surgery. However, blood tests for parameters such as D-dim-
er were not performed. As no guidelines have been estab-
lished regarding the timing, method, or dosage of recombi-
nant activated factor VII administration, the establishment 
of indications for the use of VII preparations based on the 
accumulation of relevant cases is important. 
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